FDA approves Retatrutide this year?

What would move this market

• Launches, benchmark and leaderboard results, filings (an S-1 before an IPO), earnings and market caps, and regulators' decisions.
• At 2% Yes is a long shot. Long shots tend to be slightly overpriced, and a confirming headline can multiply the price quickly.
• Thin book: about $8k of liquidity, so one large order can move the price on its own. Treat small moves with care.

How it resolves

The rules, word for word as Polymarket publishes them:

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Closes:

1 Jan 2027, 04:59 UTC

How results are settled:

Polymarket markets are typically settled through UMA's optimistic oracle: a result is proposed after the event, can be disputed during a challenge window, and is final once undisputed or decided.

Source market on Polymarket

How to read these odds

A share of each outcome costs its chance in cents and pays $1 if it happens, so 2% means about 2¢ a share and roughly 47x back if right. The prices of all outcomes add up to about 100%. Guides: reading Polymarket odds, odds to probability, glossary.